Skip to main content
Cisen Pharmaceutical Co.,Ltd. logo

Cisen Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 603367 ISIN · CNE100002VG4 LEI · 836800T7RRJXURVHYS35 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,110 across all filing types
Latest filing 2025-04-21 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603367

About Cisen Pharmaceutical Co.,Ltd.

https://www.cisen-pharma.com/

Cisen Pharmaceutical Co.,Ltd. is a comprehensive enterprise dedicated to the research, development, production, and marketing of a diverse range of medicinal products. The company specializes in the manufacture of large-volume injections, small-volume injections, and solid oral dosage forms, including tablets and capsules. Its product portfolio addresses critical therapeutic areas such as parenteral nutrition, anti-infectives, cardiovascular health, and anesthesia. Cisen Pharmaceutical maintains an integrated value chain, producing both active pharmaceutical ingredients (APIs) and finished formulations. The organization emphasizes technological innovation and stringent quality management systems to ensure the efficacy and safety of its medical solutions. By leveraging advanced manufacturing capabilities and a robust distribution network, the company provides essential healthcare products to clinical institutions and medical providers.

Recent filings

Filing Released Lang Actions
中泰证券股份有限公司关于辰欣药业股份有限公司2024年度募集资金存放与实际使用情况的专项核查报告
Regulatory Filings
2025-04-21 Chinese
大信会计师事务所（特殊普通合伙）关于辰欣药业股份有限公司的审计报告
Regulatory Filings
2025-04-21 Chinese
辰欣药业股份有限公司关于2024年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集资金存放与实际使用情况的专项报告" which translates to "Special Report on the Storage and Actual Use of Raised Funds" for the year 2024 by 辰欣药业股份有限公司. It details the amount of funds raised, their storage, usage, management, changes in investment projects, and compliance with regulatory requirements. The document references regulatory guidelines related to the management and use of raised funds, including specific approvals and agreements with banks for fund custody. It includes detailed financial figures on the raised funds, their allocation, usage, and remaining balances, as well as explanations of changes in investment projects and the reasons for any surplus or unused funds. The document is comprehensive and focused specifically on the management and use of capital raised by the company, which aligns with the definition of a Capital/Financing Update (CAP) filing. It is not a general annual or interim report, nor is it an announcement or certification. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-04-21 Chinese
辰欣药业股份有限公司关于2024年度利润分配方案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2024 annual profit distribution plan of the company 辰欣药业股份有限公司. It details the cash dividend per share, total dividend amount, and the decision-making process including board and supervisory opinions. It explicitly states that the profit distribution plan will be submitted to the shareholders' meeting for approval. The document does not contain full financial statements or comprehensive financial performance data, but rather focuses on dividend distribution details and related procedural information. This fits the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and details for shareholders. The document length is 2302 characters, which is relatively short and consistent with a dividend announcement rather than a full annual report or interim report.
2025-04-21 Chinese
大信会计师事务所（特殊普通合伙）关于辰欣药业股份有限公司内控审计报告
Regulatory Filings
2025-04-21 Chinese
辰欣药业股份有限公司关于续聘会计师事务所的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's decision to renew the appointment of an accounting firm (auditor) for the upcoming fiscal year. It details the auditor's background, qualifications, independence, and audit fees, and mentions board and supervisory committee approvals. There are no actual financial statements or audit reports included, nor is there detailed financial analysis. The document is a formal announcement about the auditor appointment, not the audit report itself. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers miscellaneous regulatory announcements that do not fit other specific categories.
2025-04-21 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.